Approval · Notice of Compliance 37407 · 2026
BIO-AZITHROMYCIN: Notice of Compliance 37407
Issued April 27, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37407
- Date
- April 27, 2026
- Company
- Biomed PharmaMontreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- ZITHROMAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIO-AZITHROMYCIN | 02567881 | Approved |
| BIO-AZITHROMYCIN | 02567903 | Approved |
Medicinal ingredients
- AZITHROMYCIN DIHYDRATE 250 MG per TAB
- AZITHROMYCIN DIHYDRATE 600 MG per TAB